Unity Biotechnology, Inc.

NasdaqGS:UBX Stock Report

Market Cap: US$16.2m

Unity Biotechnology Past Earnings Performance

Past criteria checks 0/6

Unity Biotechnology has been growing earnings at an average annual rate of 24.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 6.5% per year.

Key information

24.2%

Earnings growth rate

43.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate6.5%
Return on equity-154.8%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Nov 05
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Nov 18
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

UNITY Biotechnology falls 7% on reverse stock split

Oct 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Aug 19

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Aug 12

A Look At Unity's UBX1325 Phase 1 Results

Jul 26

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22
Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Revenue & Expenses Breakdown

How Unity Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:UBX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-2215-6
30 Jun 240-3016-4
31 Mar 240-40180
31 Dec 230-40190
30 Sep 230-341915
30 Jun 230-332011
31 Mar 230-31190
31 Dec 220-44200
30 Sep 225-56210
30 Jun 225-59220
31 Mar 225-6423-9
31 Dec 215-61230
30 Sep 210-7023-54
30 Jun 210-8124-35
31 Mar 210-8224-11
31 Dec 200-94240
30 Sep 200-9224125
30 Jun 200-8623106
31 Mar 200-912290
31 Dec 190-82200
30 Sep 190-86190
30 Jun 190-83180
31 Mar 190-79170
31 Dec 180-761659
30 Sep 181-67140
30 Jun 181-60120
31 Mar 181-52110
31 Dec 171-45100

Quality Earnings: UBX is currently unprofitable.

Growing Profit Margin: UBX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: UBX is unprofitable, but has reduced losses over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: UBX has a negative Return on Equity (-154.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elemer PirosCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc
Andrew FeinH.C. Wainwright & Co.